A phase I study of pazopanib in patients with advanced hepatocellular carcinoma

Abstract

This journal suppl. contain 2009 ASCO Meeting AbstractsOpen Access JournalBACKGROUND: Patients (pts) with advanced hepatocellular carcinoma (HCC) have a poor prognosis. HCC is a highly vascular tumor with increased levels of angiogenic factors including VEGF and VEGFR. Pazopanib (GW786034 ) is an oral angiogenesis inhibitor targeting VEGFR, PDGFR, and c-Kit. A Phase I study was conducted to determine the maximum tolerated dose (MTD), safety, pharmacokinetics, pharmacodynamics and efficacy of pazopanib in patients with locally unresectable and/or …link_to_OA_fulltex